A Pilot, Open-Label Study in Subjects With Mild-to-Moderate Plaque Psoriasis to Investigate the Dosing Feasibility, Safety, Tolerability, and Preliminary Efficacy of a Four-Week Multi-dose Regimen of DLX105-DMP Administered to a Target Lesion
Latest Information Update: 08 May 2023
At a glance
- Drugs DLX105 DMP (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Delarrivo
Most Recent Events
- 30 Apr 2023 Status changed from recruiting to completed.
- 21 Mar 2022 Planned End Date changed from 31 May 2022 to 31 Jul 2022.
- 21 Mar 2022 Planned primary completion date changed from 31 May 2022 to 31 Jul 2022.